Selegiline
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1989
- First approval year
- 1989
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Selegiline
- Molecular weight
- 187.29
- Structure (SMILES)
- C#CCN(C)[C@H](C)Cc1ccccc1
- emsam
- Emsam
- (-)-(N)-METHYL-N-((1R)-1-METHYL-2-PHENYLETHYL)PROP-2-YN-1-AMINE
- benzeneethanamine n alpha methyl n 2 propynyl alpha r
- BENZENEETHANAMINE, N,.ALPHA.-METHYL-N-2-PROPYNYL-, (.ALPHA.R)-
- emsam
- EmSam
- EMSAM (Selegiline Transdermal System) 12mg
- EMSAM (Selegiline Transdermal System) 6mg
- l selegiline
- L-selegiline
- n methyl n 1r 1 methyl 2 phenylethyl prop 2 yn 1 amine
- selegilina
- Selegilina
- selegiline
- Selegiline
- selegiline [INN]
- SELEGILINE [MI]
- SELEGILINE [ORANGE BOOK]
- SELEGILINE [USAN]
- SELEGILINE [VANDF]
- Selegiline [WHO-DD]
- selegiline inn
- selegiline mi
- selegiline orange book
- selegiline usan
- selegiline vandf
And 1 more, listed on the interactive page.
- ATC classification codes
- N04BD01
Sources for recorded values
- CAS registry numbers
- 14611-51-9
- ChEMBL ID
- CHEMBL972
- InChIKey
- MEZLKOACVSPNER-GFCCVEGCSA-N
- PubChem compound IDs
- 26757
- FDA ingredient codes (UNII)
- 2K1V7GP655
- 9639
- 203137
- Applicant
- SOMERSET
- Approval date
- 27 Feb 2006
- Application number
- NDA021336
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- selegiline
- Type
- Synthetic organic
- Drug name stem
- -giline
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- topical
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Monoamine oxidase A
- Gene symbol
- MAOA
- Protein identifier
- P21397
- Median affinity
- 4.17
- Affinity units
- pKi
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Monoamine oxidase B
- Gene symbol
- MAOB
- Protein identifier
- P27338
- Affinity units
- pKi
- Primary target
- Yes
- Mechanism
- Monoamine oxidase B inhibitor
- Action type
- Inhibitor
- Target
- Amine oxidase [flavin-containing] B
- Protein identifier
- P27338
Open Targets mechanisms
- Mechanism
- Monoamine oxidase B inhibitor
- Action type
- Inhibitor
- Target
- Amine oxidase [flavin-containing] B
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- MAOB
- Protein identifier
- P27338
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
- Condition
- Cocaine-Related Disorders
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002610
- Subject identifier
- D019970
- Condition
- Tobacco Use Disorder
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003768
- Subject identifier
- D014029
- Condition
- Amphetamine-Related Disorders
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004701
- Subject identifier
- D019969
- Condition
- Borderline Personality Disorder
- Highest recorded phase
- 3
- Condition identifier
- HP:0012076
- Subject identifier
- D001883
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0002009
- Subject identifier
- D003865
- Condition
- Depressive Disorder
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0002050
- Subject identifier
- D003866
- Condition
- Schizophrenia
- Highest recorded phase
- 0.5
- Condition identifier
- MONDO:0005090
- Subject identifier
- D012559
- Condition
- Parkinson Disease
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0005180
- Subject identifier
- D010300
- Condition identifier
- EFO_0002610
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003768
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004318
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004319
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004701
- Highest recorded phase
- 1
- Condition identifier
- EFO_0010445
- Highest recorded phase
- 2
- Condition identifier
- HP_0012076
- Highest recorded phase
- 3
- Condition identifier
- HP_0100543
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001627
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002009
- Condition identifier
- MONDO_0002009
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0002050
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005082
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005090
- Condition identifier
- MONDO_0005090
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005180
- Condition identifier
- MONDO_0005180
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005186
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005689
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008575
- Highest recorded phase
- 2
Warnings
- Warning
- Black Box Warning
- Effect
- psychiatric toxicity
Open Targets warnings
- Warning
- Black Box Warning
- Effect
- psychiatric toxicity
- Country
- United States
- Event
- adrenal medulla hyperfunction
- Reports
- 1
- Reporting signal score
- 8.22141
- Event
- application site burn
- Reports
- 4
- Reporting signal score
- 12.2733
- Event
- application site discolouration
- Reports
- 4
- Reporting signal score
- 13.4254
- Event
- application site discomfort
- Reports
- 3
- Reporting signal score
- 9.81673
- Event
- application site erythema
- Reports
- 52
- Reporting signal score
- 217.437
- Event
- application site irritation
- Reports
- 21
- Reporting signal score
- 86.6545
- Event
- application site pain
- Reports
- 10
- Reporting signal score
- 23.7865
- Event
- application site pruritus
- Reports
- 30
- Reporting signal score
- 118.408
- Event
- application site rash
- Reports
- 56
- Reporting signal score
- 272.901
- Event
- application site reaction
- Reports
- 20
- Reporting signal score
- 89.9713
- Event
- application site scar
- Reports
- 3
- Reporting signal score
- 12.2434
- Event
- application site swelling
- Reports
- 3
- Reporting signal score
- 8.94903
- Event
- application site urticaria
- Reports
- 14
- Reporting signal score
- 73.62
- Event
- application site vesicles
- Reports
- 6
- Reporting signal score
- 19.0626
- Event
- balance disorder
- Reports
- 11
- Reporting signal score
- 10.1838
- Event
- blood pressure increased
- Reports
- 13
- Reporting signal score
- 8.14335
- Event
- burning mouth syndrome
- Reports
- 3
- Reporting signal score
- 12.9486
- Event
- delusion
- Reports
- 9
- Reporting signal score
- 17.5944
- Event
- depression
- Reports
- 29
- Reporting signal score
- 25.6951
- Event
- dermatitis contact
- Reports
- 7
- Reporting signal score
- 16.0874
- Event
- diarrhoea
- Reports
- 1
- Reporting signal score
- 13.8895
- Event
- disease recurrence
- Reports
- 11
- Reporting signal score
- 17.7252
- Event
- dopamine dysregulation syndrome
- Reports
- 15
- Reporting signal score
- 82.7336
- Event
- dropped head syndrome
- Reports
- 2
- Reporting signal score
- 8.21868
- Event
- drug interaction
- Reports
- 24
- Reporting signal score
- 13.5521
And 32 more, listed on the interactive page.
- NCT00000188
- NCT00000201
- NCT00000336
- NCT00000337
- NCT00032929
- NCT01495195
- NCT00033072
- NCT00129311
- NCT00439413
- NCT01330030
- NCT00285766
- NCT00443872
- NCT00640159
- NCT04870372
- NCT00456976
- NCT00531947
- NCT01912391
- NCT04586543
- Dose
- 10mg
- How often
- Twice daily
- Hydrogen bond acceptors
- 1
- Hydrogen bond donors
- 0
- Polar surface area
- 3.24
- Calculated partition coefficient (ALogP)
- 2.18
- Calculated partition coefficient (XLogP)
- 2.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 14
- Molecular formula
- C13H17N
- Monoisotopic mass
- 187.136099547
- Natural product
- Yes
- 49502-900
- 49502-901
- 49502-902
- Recorded assays
- 1,489
- Active assays
- 228
- Confirmatory
- Other
- Antidepressive Agents
- Antiparkinson Agents
- Monoamine Oxidase Inhibitors
- Neuroprotective Agents
Distribution coefficient (LogD)
- Median
- 3.15
- Mean
- 2.655
- Minimum
- 0.62
- Maximum
- 3.7
- Unit
- unitless
- Assays
- 4
- Standard deviation
- 1.42925
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Solubility
- Median
- 575
- Mean
- 575
- Minimum
- 575
- Maximum
- 575
- Unit
- ug/mL
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Solubility
Related records
Trials (24)
- A Pilot Study Assessing EmSam in Bipolar Depression
- A Study to Assess the Bioavailability and Adhesion of Selegiline TDS in Healthy Subjects
- A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects
- Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1
- Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder
- Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma
- Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior
- Determine the Bioavailability of Selegiline TDS 6mg/24 Hours vs EMSAM in Healthy Subjects
- Efficacy of Selegiline in Negative Symptoms of Schizophrenia
- Evaluation of Adhesion and Dermal Tolerability of EMSAM
- Infusion Laboratory: Protocol 1 - Selegeline - 2
- Pharmacological Modulation of Cocaine Effects - 1
- Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression
- PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly
- Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression
- Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
- Selegiline for Smoking Cessation - 1
- Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease
- Selegiline in Outpatient Treatment for Cocaine Dependence - 1
- Selegiline in Treatment of Cocaine Dependence - 2
Approved for (2)
In development for (7)
- Borderline personality disorder Phase 3
- Cocaine dependence Phase 3
- Depressive disorder Phase 3
- Methamphetamine dependence Phase 1
- Nicotine dependence Phase 2
- Prostate adenocarcinoma Phase 2
- Schizophrenia Early phase 1
Targets (1)
- MAOB Monoamine oxidase B inhibitor